Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate (vol 16, pg 888, 2010)

被引：1
|
作者：
Okeley, N. M.
Miyamoto, J. B.
Zhang, X.
Sanderson, R. J.
Benjamin, D. R.
Sievers, E. L.
机构：
来源：
CLINICAL CANCER RESEARCH | 2011年 / 17卷 / 16期
关键词：
D O I：
10.1158/1078-0432.CCR-11-1753
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5524 / 5524
页数：1
相关论文
共 50 条
  • [21] Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma
    Younes, A.
    Forero-Torres, A.
    Bartlett, N. L.
    Leonard, J. P.
    Rege, B.
    Kennedy, D. A.
    Lorenz, J. M.
    Sievers, E. L.
    ANNALS OF ONCOLOGY, 2008, 19 : 129 - 129
  • [22] The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.
    Fanale, Michelle
    Bartlett, Nancy L.
    Forero-Torres, Andres
    Rosenblatt, Joseph
    Horning, Sandra J.
    Franklin, Anna R.
    Lynch, Carmel M.
    Sievers, Eric L.
    Kennedy, Dana A.
    BLOOD, 2009, 114 (22) : 1068 - 1069
  • [23] Antibody-Drug Conjugate Made of Zoledronic Acid and the Anti-CD30 Brentuximab-Vedotin Exert Anti-Lymphoma and Immunostimulating Effects
    Morelli, Feliciana
    Matis, Serena
    Benelli, Roberto
    Salvini, Laura
    Zocchi, Maria Raffaella
    Poggi, Alessandro
    CELLS, 2024, 13 (10)
  • [24] Treating iPSC-Derived β Cells with an Anti-CD30 Antibody-Drug Conjugate Eliminates the Risk of Teratoma Development upon Transplantation
    Pellegrini, Silvia
    Zamarian, Valentina
    Landi, Elisa
    Cospito, Alessandro
    Lombardo, Marta Tiffany
    Manenti, Fabio
    Citro, Antonio
    Lena, Marco Schiavo
    Piemonti, Lorenzo
    Sordi, Valeria
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (17)
  • [25] ROBUST ANTITUMOR ACTIVITY OF THE ANTIBODY-DRUG CONJUGATE SGN-35 WHEN ADMINISTERED EVERY 3 WEEKS TO PATIENTS WITH RELAPSED OR REFRACTORY CD30 POSITIVE HEMATOLOGIC MALIGNANCIES IN A PHASE 1 STUDY
    Younes, A.
    Forero-Torres, A.
    Bartlett, N. L.
    Leonard, J. P.
    Kennedy, D. A.
    Sievers, E. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 205 - 205
  • [26] SGN-CD48A: a Novel Humanized Anti-CD48 Antibody-Drug Conjugate for the Treatment of Multiple Myeloma
    Lewis, Tim S.
    Olson, Devra
    Gordon, Kristine
    Sandall, Sharsti
    Quick, Marsha
    Finn, Margo
    Westendorf, Lori
    Linares, Germein
    Leiske, Chris
    Nesterova, Albina
    Huang, Lanshan
    Goswami, Maitrayee
    Wang, Sa
    Law, Che-Leung
    BLOOD, 2016, 128 (22)
  • [27] SGN-CD228A: A novel humanized anti-CD228 antibody-drug conjugate for the treatment of solid tumors
    Sandall, Sharsti L.
    Mason, Marsha
    Olson, Devra
    Mazahreh, Rebecca
    Sahetya, Disha
    Westendorf, Lori
    Leiske, Chris
    Schimpf, Brian
    Nguyen, Liem
    Katepalli, Madhu
    Trueblood, Esther
    Hale, Christopher
    Nesterova, Albina
    Wall, Jason
    Lewis, Timothy S.
    CANCER RESEARCH, 2019, 79 (13)
  • [28] Maturing antibody-drug conjugate pipeline hits 30 (vol 12, pg 329, 2013)
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (06) : 483 - 483
  • [29] Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives
    H. Miles Prince
    Martin Hutchings
    Eva Domingo-Domenech
    Dennis A. Eichenauer
    Ranjana Advani
    Annals of Hematology, 2023, 102 : 13 - 29
  • [30] SGN-CD30C, an Investigational CD30-Directed Camptothecin Antibody-Drug Conjugate (ADC), Shows Strong Anti Tumor Activity and Superior Tolerability in Preclinical Studies
    Ryan, Maureen
    Lyski, Ryan
    Bou, Lauren
    Heiser, Ryan
    Grogan, Bryan
    Meyer, Dave
    Jin, Steven
    Simmons, Jessica
    Conerly, Melissa
    Senter, Peter
    Jeffrey, Scott
    BLOOD, 2020, 136
12345